Avaliação de cultivares de gergelim no outono - inverno na região Norte-Fluminense.

bitstream/CNPA/18341/1/BOLETIM73.pd

Produtividade de linhagens avançadas de amendoim em condições de sequeiro no Nordeste brasileiro.

Onze linhagens avançadas de amendoim, eretas e rasteiras, foram conduzidas em condições de sequeiro, em quatro estados nordestinos, visando-se avaliar a produtividade em vagens e sementes. Os ensaios foram conduzidos no período de 2005 a 2007, nos municípios de Araripina e Parnamirim, PE, Lagarto, SE, Cruz das Almas e Caetité, BA, Campina Grande e Itabaiana, PB. O delineamento experimental adotado foi em blocos ao acaso, com 13 tratamentos, constituídos de oito linhagens eretas e cinco rasteiros, com cinco repetições. As variáveis analisadas foram produtividades de vagens e de sementes. Em referência à análise estatística, realizaram-se análises de variância individual e conjunta e se adotou o teste de Tukey (p < 0,05) para comparação das médias dos tratamentos. A cultivar BR 1 foi utilizada como testemunha entre os genótipos eretos. A linhagem ereta LN-1B apresentou maior produção de vagens entre as demais do grupo, com 2.450 kg ha-1, superando a média em 22% e a BR 1, em 11%; a produtividade média em sementes situou-se em 1.665 kg ha-1, correspondendo a 21% acima da média do grupo e 10% acima da BR 1. Entre as linhagens rasteiras as médias de produtividade em vagens e em sementes foram consideradas baixas nas condições estudadas destacando-se, contudo, LI-3, LI-5 e LI-1, que produziram em média entre 1.722 kg ha-1 e 1.154 kg ha-1, e superaram a média do grupo em 9.8 e 10%, respectivamente

Poly(dimethylsiloxane) as a pre-coating in layer-by-layer films containing phosphotungstate nanoclusters electrochemically sensitive toward s-triazines

One of the major advantages of the Layer-by-Layer (LbL) deposition technique is the possible control of molecular architecture, not only to achieve optimized properties but also to seek synergy among different materials. In this study, LbL films containing nanoclusters of a Keggin type polyoxometalate, phosphotungstic acid (HPW), alternated with the polycation poly(allylamine hydrochloride) (PAH) were deposited on indium-tin oxide (ITO) substrates. The electrochemical properties of the hybrid LbL film investigated in acidic conditions indicated no significant desorption of HPW, when a layer of poly(dimethylsiloxane) terminated with 3-aminopropyl groups (PDMS) was previously deposited on the ITO substrate. Such effect occurred because PDMS prevents desorption of HPW from the hybrid film, as shown by X-ray Photoelectron Spectroscopy (XPS) analyses. The porous structures of the films were revealed by Fourier transform infrared reflection absorption spectroscopy, scanning electron microscopy and XPS. PDMS/PAH as a pre-coating allowed the HPW/PAH films to be sensitive to the electrochemical detection of the triazines atrazine and melamine. In conclusion, the precise control of the LbL films architecture is important to develop opportunities for new applications. © 2014 The Royal Society of Chemistry.One of the major advantages of the Layer-by-Layer (LbL) deposition technique is the possible control of molecular architecture, not only to achieve optimized properties but also to seek synergy among different materials. In this study, LbL films containin4562961229621FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOCAPES - COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIORsem informaçãosem informaçãosem informaçãoDecher, G., (1997) Science, 277, p. 1232Stockton, W.B., Rubner, M.F., (1997) Macromolecules, 30, p. 2717Shimazaki, Y., Mitsuishi, M., Ito, S., Yamamoto, M., (1997) Langmuir, 13, p. 1385Kohli, P., Blanchard, G.J., (2000) Langmuir, 16, p. 8518Anzai, J., Kobayashi, Y., (2000) Langmuir, 16, pp. 2851-2856Shi, X., Shen, M., Mohwald, H., (2004) Prog. Polym. Sci., 29, p. 987Zucolotto, V., Ferreira, M., Cordeiro, M.R., Constantino, C.J.L., Moreira, W.C., Oliveira Jr., O.N., (2006) Sens. Actuators, B, 113, p. 809Alexeyeva, N., Tammeveski, K., (2008) Anal. Chim. Acta, 618, p. 140Liu, S., Volkmer, D., Kurth, D.G., (2003) J. Cluster Sci., 14, p. 405Kuhn, A., Mano, N., Vidal, C., (1999) J. Electroanal. Chem., 462, p. 187Cherstiouk, O.V., Simonov, A.N., Tsirlina, G.A., (2012) Electrocatalysis, 3, p. 230Lu, M., Lee, D., Xue, W., Cui, T., (2009) Sens. Actuators, A, 150, p. 280Han, B.H., Manners, I., Winnik, M.A., (2005) Chem. Mater., 17, p. 3160Perinotto, A.C., Caseli, L., Hayasaka, C.O., Riul Jr., A., Oliveira Jr., O.N., Zucolotto, V., (2008) Thin Solid Films, 516, p. 9002Moraes, M.L., De Souza, N.C., Hayasaka, C.O., Ferreira, M., Rodrigues-Filho, U.P., Riul Jr., A., Zucolotto, V., Oliveira Jr., O.N., (2009) Mater. Sci. Eng., C, 29, p. 442Liu, S., Mohwald, H., Volkmer, D., Kurth, D.G., (2006) Langmuir, 22, p. 1949Katsoulis, D.E., (1998) Chem. Rev., 98, p. 359Papaconstantinuou, E., (1989) Chem. Soc. Rev., 18, p. 1Timofeeva, M.N., (2003) Appl. Catal., A, 256, p. 19Sadakane, M., Steckhan, E., (1998) Chem. Rev., 98, p. 219Yamase, T., (1998) Chem. Rev., 98, p. 307De Oliveira Jr., M., Lopes De Souza, A., Schneider, J., Pereira Rodrigues-Filho, U., (2011) Chem. Mater., 23, p. 953Ferreira-Neto, E.P., De Carvalho, F.L.S., Ullah, S., Zoldan, V.C., Pasa, A.A., De Souza, A.L., Battirola, L.C., Rodrigues Filho, U.P., (2013) J. Sol-Gel Sci. Technol., 66, p. 363Souza, A.L., Marques, L.A., Eberlin, M.N., Nascente, P.A.P., Herrmann Jr., P.S.P., Leite, F.L., Rodrigues-Filho, U.P., (2012) Thin Solid Films, 520, p. 3574Liu, S., Tang, Z., (2010) Nano Today, 5, p. 267Dong, T., Ma, H., Zhang, W., Gong, L., Wang, F., Li, C., (2007) J. Colloid Interface Sci., 311, p. 523Ma, H., Dong, T., Wang, F., Zhang, W., Zhou, B., (2006) Electrochim. Acta, 51, p. 4965Cheng, L., Cox, J.A., (2002) Chem. Mater., 14, p. 6Gu, Y., Ma, H., O'Halloran, K.P., Shi, S., Zhang, Z., Wang, X., (2009) Electrochim. Acta, 54, p. 7194Kulesza, P.J., Chojak, M., Karnicka, K., Miecznikowski, K., Palys, B., Lewera, A., Wieckowski, A., (2004) Chem. Mater., 16, p. 4128Ernst, A.Z., Zoladek, S., Wiaderek, K., Cox, J.A., Kolary-Zurowska, A., Miecznikowski, K., Kulesza, P.J., (2008) Electrochim. Acta, 53, p. 3924Sun, L., Ca, D.V., Cox, J.A., (2005) J. Solid State Electrochem., 9, p. 816Liu, S., Kurth, D.G., Bredenkotter, B., Volkmer, D., (2002) J. Am. Chem. Soc., 124, p. 12279Cheng, L., Cox, J.A., (2001) Electrochem. Commun., 3, p. 285Feng, Y., Han, Z., Peng, J., Lu, J., Xue, B., Li, L., Ma, H., Wang, E., (2006) Mater. Lett., 60, p. 1588Xu, B., Xu, L., Gao, G., Jin, Y., (2007) Appl. Surf. Sci., 253, p. 3190Cheng, L., Dong, S., (2000) J. Electrochem. Soc., 147, p. 606Fernandes, D.M., Carapuça, H.M., Brett, C.M.A., Cavaleiro, A.M.V., (2010) Thin Solid Films, 518, p. 5881Cheng, L., Dong, S., (2000) J. Electroanal. Chem., 481, p. 168Liu, S., Volkmer, D., Kurth, D.G., (2004) Anal. Chem., 76, p. 4579Sosnowska, M., Goral-Kurbiel, M., Skunik-Nuckowska, M., Jurczakowski, R., Kulesza, P.J., (2013) J. Solid State Electrochem., 17, p. 1631Layla Mehdi, B., Rutkowska, I.A., Kulesza, P.J., Cox, J.A., (2013) J. Solid State Electrochem., 17, p. 1581Shiu, K.-K., Anson, F.C., (1991) J. Electroanal. Chem., 309, p. 115Martel, D., Kuhn, A., (2000) Electrochim. Acta, 45, p. 1829Chan, Z.C.Y., Lai, W.-F., (2009) Trends Food Sci. Technol., 20, p. 366Gammon, D.W., Aldous, C.N., Carr Jr., W.C., Sanborn, J.R., Pfeifer, K.F., (2005) Pest Manage. Sci., 61, p. 331Yu, J., Zhang, C., Dai, P., Ge, S., (2009) Anal. Chim. Acta, 651, p. 209Shoji, R., Takeuchi, T., Kubo, I., (2003) Anal. Chem., 75, p. 4882Donley, C., Dunphy, D., Paine, D., Carter, C., Nebesny, K., Lee, P., Alloway, D., Armstrong, N.R., (2002) Langmuir, 18, p. 450Sawyer, D.T., Sobkowiak, A., Roberts Jr., J.L., (1995) Electrochemistry for Chemists, pp. 68-78. , John Wiley & Sons, New York, 2nd edn, ch. 3Beamson, G., Briggs, D., (1992) High Resolution of XPS of Organic Polymers: The Scienta ESCA 300 Database, , John Wiley & Sons, ChichesterPope, M.T., Varga Jr., G.M., (1966) Inorg. Chem., 5, p. 1249Keita, B., Nadjo, L., (1987) J. Electroanal. Chem., 227, p. 77Stotter, J., Show, Y., Wang, S., Swain, G., (2005) Chem. Mater., 17, p. 4880Senthilkumar, M., Mathiyarasu, J., Joseph, J., Phani, K.L.N., Yegnaraman, V., (2008) Mater. Chem. Phys., 108, p. 403Vanleugenhague, C., Pourbaix, M., (1966) Atlas of Electrochemical Equilibra in Aqueous Solution, pp. 436-442. , ed. M. Pourbaix, Pergamon Press, OxfordDeltombe, E., De Zoubov, N., Vanleugenhague, C., Pourbaix, M., (1966) Atlas of Electrochemical Equilibra in Aqueous Solution, pp. 475-484. , ed. M. Pourbaix, Pergamon Press, OxfordPope, M.T., (1987) Comprehensive Coordination Chemistry, 3, p. 1039. , ed. G. Wilkinson, R. D. Gillard and J. A. McCleverty, Plenum Press, New YorkAkhtar, M.S., Cheralathan, K.K., Chun, J.M., Yang, O.B., (2008) Electrochim. Acta, 53, p. 6623Oliveira, F.C., Schneider, J., Siervo, A., Landers, R., Plepis, A.M.G., Pireaux, J.J., Rodrigues-Filho, U.P., (2002) Surf. Interface Anal., 34, p. 580Zhang, L., Jin, Q., Huang, J., Liu, Y., Shan, L., Wang, X., (2010) Appl. Surf. Sci., 256, p. 5911(2011) X-Ray Photoelectron Spectroscopy Database, Standard Database 20, Version 3.5, , http://srdata.nist.gov/xps/Version_his.aspxNunes De Carvalho, C., Botelho Do Rego, A.M., Amaral, A., Brogueira, P., Lavareda, G., (2000) Surf. Coat. Technol., 124, p. 70Lourenço, J.M.C., Ribeiro, P.A., Botelho Do Rego, A.M., Braz Fernandes, F.M., Moutinho, A.M.C., Raposo, M., (2004) Langmuir, 20, p. 8103Liu, Y.T., Deng, J., Xiao, X.L., Ding, L., Yuan, Y.L., Li, H., Li, X.T., Wang, L.L., (2011) Electrochim. Acta, 56, p. 4595Liao, C.W., Chen, Y.-R., Chang, J.-L., Zen, J.-M., (2011) J. Agric. Food Chem., 59, p. 9782Akter, H., Shaikh, A.A., Chowdhury, T.R., Rahmam, M.S., Bakshi, P.K., Saleh Ahammad, A.J., (2013) ECS Electrochem. Lett., 2 (8), p. 13Tran, H.V., Yougnia, R., Reisberg, S., Piro, B., Serradji, N., Nguyen, T.D., Tran, L.D., Pham, M.C., (2012) Biosens. Bioelectron., 31, p. 62Norouzi, P., Larijani, B., Ganjali, M.R., Faridbod, F., (2012) Int. J. Electrochem. Sci., 7, p. 10414Xu, G., Zhang, H., Zhong, M., Zhang, T., Lu, X., Kan, X., (2014) J. Electroanal. Chem., 713, p. 112Pesavento, M., D'Agostino, G., Biesuz, R., Alberti, G., (2009) Electroanalysis, 21, p. 604Svorc, L., Rievaj, M., Bustin, D., (2013) Sens. Actuators, B, 181, p. 294This work was supported by FAPESP, CNPq, CAPES and Brazilian Network nBioNe

The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

In approximately 15% of patients with acute myeloid leukemia (AML), total and phosphorylated EGFR proteins have been reported to be increased compared to healthy CD34(+) samples. However, it is unclear if this subset of patients would benefit from EGFR signaling pharmacological inhibition. Pre-clinical studies on AML cells provided evidence on the pro-differentiation benefits of EGFR inhibitors when combined with ATRA or ATO in vitro. Despite the success of ATRA and ATO in the treatment of patients with acute promyelocytic leukemia (APL), therapy-associated resistance is observed in 5-10% of the cases, pointing to a clear need for new therapeutic strategies for those patients. In this context, the functional role of EGFR tyrosine-kinase inhibitors has never been evaluated in APL. Here, we investigated the EGFR pathway in primary samples along with functional in vitro and in vivo studies using several APL models. We observed that total and phosphorylated EGFR (Tyr992) was expressed in 28% and 19% of blast cells from APL patients, respectively, but not in healthy CD34(+) samples. Interestingly, the expression of the EGF was lower in APL plasma samples than in healthy controls. The EGFR ligand AREG was detected in 29% of APL patients at diagnosis, but not in control samples. In vitro, treatment with the EGFR inhibitor gefitinib (ZD1839) reduced cell proliferation and survival of NB4 (ATRA-sensitive) and NB4-R2 (ATRA-resistant) cells. Moreover, the combination of gefitinib with ATRA and ATO promoted myeloid cell differentiation in ATRA- and ATO-resistant APL cells. In vivo, the combination of gefitinib and ATRA prolonged survival compared to gefitinib- or vehicle-treated leukemic mice in a syngeneic transplantation model, while the gain in survival did not reach statistical difference compared to treatment with ATRA alone. Our results suggest that gefitinib is a potential adjuvant agent that can mitigate ATRA and ATO resistance in APL cells. Therefore, our data indicate that repurposing FDA-approved tyrosine-kinase inhibitors could provide new perspectives into combination therapy to overcome drug resistance in APL patients

Estudo expedito de solos no estado do Maranhão para fins de classificação, correlação e legenda preliminar.

O trabalho em foco constitui o informe técnico do estudo expedito de solos realizado na área da Pré-Amazônia Maranhense em setembro de 1976 e posteriormente, em novembro de 1979, no restante do Estado do Maranhão. Foi executado pelo Serviço Nacional de Levantamento e Conservação de Solos da EMBRAPA, através do Convênio EMBRAPA/SNLCS-SUDENE/DRN, tendo contado também com recursos do Programa POLAMAZÔNIA para a realização dos trabalhos de campo da área da Pré-Amazônia Maranhense. A primeira viagem (C-1) teve a duração de seis dias de campo e a segunda (C-2) foi feita num período de nove dias, perfazendo um percurso total de aproximadamente 4.752 km, durante o qual foram estudados 138 perfis de solos. Visando ao estudo das características físicas, químicas e mineralógicas, foram colhidas amostras de 54 perfis de solos em cortes de estradas ou através de tradagem, totalizando 110 amostras. Na área em questão, foi feita a identificação de vários solos, tendo-se estudado sumariamente suas características morfológicas, físicas, químicas e mineralógicas. Além disso foram feitas observações sobre vegetação, relevo e altitude, geologia, material originário e uso agrícola dos diversos solos. Os registros das observações realizadas, relativas aos perfis estudados e condições do meio ambiente onde se encontram, são apresentados de forma condensada neste relatóriobitstream/item/62768/1/CNPS-BOL.-TEC.-61-80.pdfConvênio de mapeamento de solos EMBRAPA/SNLCS-SUDENE/DRN e Programa Especial Polamazônia

Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group

Neuroendocrine tumours are a heterogeneous group of diseases with a significant variety of diagnostic tests and treatment modalities. Guidelines were developed by North American and European groups to recommend their best management. However, local particularities and relativisms found worldwide led us to create Brazilian guidelines. Our consensus considered the best feasible strategies in an environment involving more limited resources. We believe that our recommendations may be extended to other countries with similar economic standards.Univ Sao Paulo, Inst Canc Estado Sao Paulo, BR-01246000 Sao Paulo, BrazilUniv Sao Paulo, Fac Med, Dept Radiol & Oncol, BR-01246903 Sao Paulo, BrazilHosp Sirio Libanes, BR-01308050 Sao Paulo, BrazilHosp Moinhos de Vento Porto Alegre, BR-90035000 Porto Alegre, RS, BrazilOncoctr, BR-30360680 Belo Horizonte, MG, BrazilUniv Fed Rio Grande do Sul, Dept Cirurgia, BR-90040060 Porto Alegre, RS, BrazilHosp Clin Porto Alegre, BR-90035903 Porto Alegre, RS, BrazilUniv Fed Ceara, Fac Med, Dept Fisiol & Farmacol, BR-60020180 Fortaleza, Ceara, BrazilHosp Univ Walter Cantidio, BR-60430370 Fortaleza, Ceara, BrazilInst Nacl Canc, BR-20230240 Rio De Janeiro, BrazilUniv Sao Paulo, Fac Med, Disciplina Endocrinol & Metabol, BR-01246903 Sao Paulo, BrazilAC Camargo Canc Ctr, Dept Surg, BR-01509010 Sao Paulo, BrazilUniv Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, BrazilUniv Fed Ciencias Saude Porto Alegre, BR-90050170 Porto Alegre, RS, BrazilHosp Albert Einstein, BR-05652900 Sao Paulo, BrazilHosp Base, Fac Med Sao Jose do Rio Preto, BR-15090000 Sao Paulo, BrazilSanta Casa Sao Jose do Rio Preto, BR-15025500 Sao Jose Do Rio Preto, BrazilPontificia Univ Catolica Parana, Hosp Erasto Gaertner, BR-81520060 Curitiba, Parana, BrazilUniv Fed Rio Grande do Norte, BR-59300000 Natal, RN, BrazilUniv Sao Paulo, Inst Coracao, BR-05403900 Sao Paulo, BrazilAC Camargo Canc Ctr, Med Oncol, BR-01509010 Sao Paulo, BrazilUniv Fed Sao Paulo, Disciplina Gastroenterol, BR-04021001 Sao Paulo, BrazilHosp Sao Rafael, BR-41253190 Salvador, BA, BrazilHosp Canc Barretos, Dept Cirurgia Aparelho Digest Alto & Hepatobiliop, BR-14784400 Sao Paulo, BrazilUniv Sao Paulo, Fac Med, Dept Patol, BR-01246903 Sao Paulo, BrazilClin AMO, BR-1950640 Salvador, BA, BrazilHosp Sao Jose, BR-01323001 Sao Paulo, BrazilUniv Nove de Julho, BR-02111030 Sao Paulo, BrazilUniv Fed Sao Paulo, Disciplina Gastroenterol, BR-04021001 Sao Paulo, BrazilWeb of Scienc

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): study protocol for a randomized controlled trial

BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). METHODS/DESIGN: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH2O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure 6430 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. DISCUSSION: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration metho

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals